One of the most important things we can do to affect our health and promote longevity is to learn whether or not we have cancer. It is particularly important to screen for early forms of cancer so that we can eradicate them before they become a serious problem. Until now, it has not been possible or practical to screen for many common cancers. However, there is a new test available that enables us to screen for the presence of malignant cells in your body in such small numbers that upon their discovery it is easy to destroy them before they grow into a clinically significant cancer. As it turns out, every malignant cell in the body has on its surface certain protein markers that are not only specific to malignancy, but specific to the organ of origin. When the malignant cells reach a critical number of 2 million cells, enough of the protein is shed into the blood to allow us to detect its presence.

How The Test Works

The blood test identifies a specific type of protein in the blood, which exists only on the surface of a malignant cancer cell. Cell-surface, cancer-specific proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for early detection in both primary and recurrent cancer. The test is a valuable complement to early intervention. The blood test will detect a cancer of 2 million cells compared to 4.5 trillion cells for a positive mammogram.

The test uses techniques known as two-dimensional gel electrophoresis and western blot analysis along with a cell-surface, cancer-specific protein-antibody for detection. The result of the blood test is presented visually. Each type of cell-surface, cancer-specific protein has a particular location (molecular weight and isoelectric point) on the blot to demonstrate the proteins presence and to identify the tissue of origin.

Cancers revealed by the cell-surface, cancer-specific protein test:


Why Choose Regeneveda

Dr. Lobe is a world renowned cancer surgeon with over 35 years of experience. He has been an investigator on numerous NIH grants for cancer and served on Inter-group Cooperative Cancer Committees to design new protocols for decades. Many of his nearly 200 publications in peer-reviewed medical journals deal with his expertise in the management of a variety of cancers, their treatment, and results. Dr. Lobe spent over 20 years at St. Jude Children’s Research Hospital, much of that time as Chief of Pediatric Surgery, Dr. Lobe was intimately involved with the early work and progress of the clinical application of stem cell therapies. Dr. Lobe is as well versed in the conventional prevention, diagnosis, and management of cancer as he is with alternative adjunctive therapies for cancer. Having the ability to provide his patients with the best therapeutic, nutritional, and immune support available at all stages of dealing with cancer is one of his greatest passions.

Sign Up for Our Waitlist

Name (required)

Email (required)

Phone (required)

Additional Information

Please leave this field empty.

Want to find out more?

Your Name (required)

Your Email (required)

Phone Number (required)

Your Message

Please leave this field empty.

FAQs about: Cancer Detection

Do the results reveal more than one type of cancer in one test?

Yes. If there is more than one tissue of origin, then more than one type of protein would be revealed and the results would indicate each tissue of origin.

How does this test compare to other cancer blood tests?

Cancer tests currently available measure elevated levels of normal physiological compounds that are always present in serum. They are typically employed post clinical diagnosis and, for the most part, are not sufficiently sensitive for very early screening. Our test detects the presence of cell-surface, cancer-specific proteins, these proteins are not normal proteins in the serum. These proteins only exist in serum when cancer is present and can be detected early in cancer development.

Do the results reveal metastasized cancer?

Because the metastasized cancer is derived from the primary cancer, the metastasized cancer has the same cell-surface, cancer-specific proteins as the tissue of origin. Therefore, the metastasized cancer would be revealed in the test, but the tissue of origin would remain the same as the primary. Example: If breast cancer has metastasized to the lung, the test result would reveal only breast cancer.

Do the results provide stage of cancer?

No. The results show either presence of cell-surface, cancer-specific proteins or no presence. There is no indication for level or stage.

Does the test always reveal tissue of origin?

Approximately 96% of the time, the test will reveal the tissue of origin. There are times when cell-surface, cancer-specific protein is present, but it is fully processed, meaning that it does not provide a molecular weight and isoelectric point which enables identification of tissue of origin.

How accurate is the test?

Based on analyses of over 800 cell-surface, cancer-specific protein samples covering 26 different kinds of cancers with clinically confirmed diagnoses:
• 99.3% were positive for cancer based on protein presence
• Of these, the organ site of the cancer was determined correctly in 96% of the samples
• There were no false positives
• There were less than 1% false negatives

Is the test approved by the FDA?

The test currently meets FDA requirements for a Laboratory Developed Test (LDT). The Test is CLIA Accredited and CAP Accredited and was made available in January 2013.